Brief: Alzamend Neuro Receives FDA "Study May Proceed" Letter For Phase I/IIA Trial For An Immunotherapy Vaccine (ALZN002) To Treat Mild To Moderate Dementia Of Alzheimer's Type

Alzamend Neuro

31/10/2022 12:22

Oct 31 (Reuters) - Alzamend Neuro Inc  ALZN.O :
    * ALZAMEND NEURO RECEIVES FDA “STUDY MAY PROCEED” LETTER FOR
PHASE
I/IIA TRIAL UNDER ITS INVESTIGATIONAL NEW DRUG APPLICATION FOR
AN IMMUNOTHERAPY VACCINE (ALZN002) TO TREAT MILD TO MODERATE
DEMENTIA OF THE ALZHEIMER’S TYPE
    * ALZAMEND NEURO INC - ADVANCING PROCESS AND EXPECT THAT
FIRST
PATIENT WILL BE DOSED IN Q1 OF 2023

Source text for Eikon:  ID:nBw8bzVswa 
Further company coverage:  ALZN.O 
 ((Reuters.Briefs@thomsonreuters.com;;))